Skip to main content
SpringerLink
Log in

Regenerative Nanomedicine: Ethical, Legal, and Social Issues

  • Protocol
  • First Online:
Book cover Nanotechnology in Regenerative Medicine

Part of the book series: Methods in Molecular Biology ((MIMB,volume 811))

Abstract

Advances in regenerative nanomedicine raise a host of ethical, legal, and social questions that healthcare providers and scientists will need to consider. These questions and concerns include definitions, appropriate applications, dual use, potential risks, regulations, and access. In this chapter, we provide an overview of the questions and concerns and recommend proactive consideration and solutions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Goss, R.J. (1992) The natural history (and mystery) of regeneration. In: Dinsmore CE (ed.). A History of Regeneration Research. Cambridge: Cambridge University Press, 7–23.

    Google Scholar 

  2. Sandler, R. (2009) Nanomedicine and nanomedical ethics, American Journal of Bioethics 9(10), 16–17.

    Article  Google Scholar 

  3. : A new vision: A future for regenerative medicine, (2009) Department of Health and Human Services. Available at http://www.hhs.gov/reference/newfuture.shtml, last accessed October 23, 2009.

  4. Daar, A.S., Greenwood, H.L. (2007) A proposed definition of regenerative medicine. Journal of Tissue Engineering and Regenerative Medicine,1, 179–84.

    Google Scholar 

  5. National Nanotechnology Initiative (NNI). Available at http://www.nano.gov/html/about/home_about.html, http://www.nano.gov/html/facts/whatIsNano.html, http://www.nano.gov/Understanding_Risk_Assessment.pdf, last accessed November 9, 2009.

  6. Alpert, S. (2008) Neuroethics and nanoethics: do we risk ethical myopia? Neuroethics 1(1), 55–68. Available at http://www.springerlink.com/content/v6352402k048qq53, last accessed November 6, 2009.

  7. Lee, K.B., Solanki, A., Kim, J.D., and Jung, J. (2009) Nanomedicine: Dynamic Integration of Nanotechnology with Biomedical Science. In Zhang, M and Xi, N: Nanomedicine, a systems approach, Pan Stanford Publishing Pte Ltd.

    Google Scholar 

  8. Mooney, E., Dockery, P., Greiser, U., Murphy, M., Barron V. (2008) Carbon Nanotubes and Mesenchymal Stem Cells: Biocompatibility, Proliferation and Differentiation Nano Letters 8(8), 2137–2143.

    Google Scholar 

  9. Stocum, D.L. (2009) Regenerative Biology and Medicine, Elsevier Press, San Diego, 28

    Google Scholar 

  10. Stem Cell Information. Bethesda, M.D: National Institutes of Health, U.S. Department f Health and Human Services, November 06, 2009. Available at: http://stemcells.nih.gov/info/basics/basics10, last accessed November 9, 2009.

  11. Wang, Z., Ruan, J., Cui, D. (2009) Advances and prospect of nanotechnology in stem cells. Nanoscale Res Letters, 4(7), 593–605.

    Article  CAS  Google Scholar 

  12. Garibaldi, S., Brunelli, C., Bavastrello, V., Ghigliotti, G., Nicolini, C. (2006) Carbon nanotube biocomptibility with cardiac muscle cells, Nanotech 17, 391–397.

    Article  CAS  Google Scholar 

  13. Panagiotis, G.K., Lehtolainen, P., Junemann-Ramirez, M., Garcia-Prieto, A., Price, A., Martin, J.F., Gadian, D.G., Pankhurst, A.Q., Lythgoe, M.F. (2009) Magnetic tagging increases delivery of circulating progenitors in vascular injury. JACC Cardiovascular Interventions, 2(8), 794.

    Article  Google Scholar 

  14. Traphagen, S., Yelick, P.C. (2009) Reclaiming a natural beauty: whole-organ engineering with natural extracellular materials, Regenerative Medicine, 4(5), 747–758

    Article  Google Scholar 

  15. Chang,W.C., Kliot, M., Sretavan, D.W. (2008) Microtechnology and nanotechnology in nerve repair, Neurol Res. 30, 10, 1053–62.

    Article  CAS  Google Scholar 

  16. Gravitz, L. (2009) Laser Show in the Surgical Suite, Technology Review, March/April 2009, MIT Press, available at http://www.technologyreview.com/biomedicine/22088/, last accessed October 25, 2009.

  17. Guo, J., Su, H., Zeng, Y., Liang, Y.X., Wong, W.M., Ellis-Behnke, R.G., So, K.F., Wu, W. (2007) Reknitting the injured spinal cord by self-assembling peptide nanofiber scaffold, Nanomedicine, 3(4), 311–21.

    Google Scholar 

  18. Science Daily, Nanoparticle-based Erectile Dysfunction Therapy Shows Promise, Sept. 20, 2009. Available at http://www.sciencedaily.com/releases/2009/09/090918181456.htm, last accessed October 30, 2009.

  19. Woodrow Wilson Report, Project on Emerging Nanotechnologies. Available at http://www.nanotech-project.us/process/assets/files/2741/18_nanotechnologyhumanhealthimpactframeworkstrategicresearch.pdf, last accessed November 9, 2009.

  20. United States Code of Federal Regulations, Part 312 and 314.

    Google Scholar 

  21. Jotterand, F. (Ed) (2009) Emerging Conceptual, Ethical, and Policy Issues in Bionanotechnology, 2009, Springer, 183–192.

    Google Scholar 

  22. U.S. Federal Food, Drug and Cosmetic Act of 1962 Section 201 (f).

    Google Scholar 

  23. White, G.B. (2009) Missing the Boat on Nanoethics. The American Journal of Bioethics, 9(10), 18–19. Available at http://www.informaworld.com/10.1080/15265160903162642, last accessed November 08, 2009

  24. Note 1: Jesse Gelsinger was an 18 year old patient who participated in a gene therapy trial for Ornithine transcarboxylase deficiency (OTCD); he died from multiple organ failure 4 days after starting treatment. His death was believed to have been triggered by a severe immune response to the adenovirus carrier and was a major setback in gene therapy. Available at http://www.ornl.gov/sci/techresources/Human_Genome/medicine/genetherapy.shtml, last accessed November 08, 2009

  25. Allhoff, F., Lin, P. (2008) Nanotechnology & Society: Current and Emerging Ethical Issues. (Dordrecht: Springer).

    Google Scholar 

  26. Schmidt, C.W. (2009) Nanotechnology-related environment, health, and safety research: examining the national strategy. Environ Health Perspect,117(4), A158–61. Available at http://www.ehponline.org/members/2009/117-4/EHP117pa158PDF.PDF, last accessed November 4, 2009.

  27. Note 2: The Asilomar Conference on Recombinant DNA was an influential conference organized to discuss the potential hazards and regulation of biotechnology, held in February 1975 at a conference center Asilomar State Beach. A group of around 140 professionals participated in the conference to draw up voluntary guidelines to ensure the safety of recombinant DNA technology. Available at http://www.wikidoc.org/index.php/Asilomar_conference_on_recombinant_DNA last accessed August 25, 2010.

  28. Fredrickson, D.S. (2001) The recombinant DNA controversy: A memoir: science, politics, and the public interest 1974–1981. Washington, D.C.: ASM Press.

    Google Scholar 

  29. Paradise, J. (2008) Developing oversight frameworks for nanobiotechnology. Minn. J.L. Sci. & Tech. 9(1), 399–416.

    Google Scholar 

  30. Kristof, N. (2009) Chemicals and our health, New York Times, July 15, 2009, available at http://www.nytimes.com/2009/07/16/opinion/16kristof.html?_r=2&ref=opinion, last accessed November 5, 2009

  31. Diamanti-Kandarakis, E., Bourguignon, J.P., Giudice, L.C., Hauser, R., Prins, G.S., Soto, A.M., Zoeller, R.T., Gore, A.C. (2009) Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr Rev. 30(4), 293–342.

    Article  CAS  Google Scholar 

  32. Jones, O.A.H., Voulvoulis, N., Lester, J.N. (2001) Human pharmaceuticals in the aquatic environment: a review. Environ Technol 22, 1383–1395.

    Article  CAS  Google Scholar 

  33. Stem Cell Information. Bethesda, MD: National Institutes of Health, U.S. Department of Health and Human Services, 2009, Available at http://stemcells.nih.gov/info/scireport/2006chapter6, last accessed October 23, 2009

  34. Munn, D. (2001) Moral Issues of Human Embryo Research. Science 293, 211.

    Article  CAS  Google Scholar 

  35. Pellegrino, E. (2000) Testimony, in National Bioethics Advisory Commission, Ethical Issues in Human Stem Cell Research, vol. III (Washington: NBAC, 2000), F-1-F-5.

    Google Scholar 

  36. Guenin, L. (2001) Morals and Primordials. Science 292, 1659–1660. Available at http://www.sciencemag.org/cgi/content/full/292/5522/1659, last accessed November 6, 2009.

  37. Brannigan, M.C. (2001) What if we assign moral status to human embryos? Genetic Eng News 12, 6.

    Google Scholar 

  38. Chan, S., Harris, J. (2008) Adam’s fibroblast? The (pluri)potential of iPCs. J MedEthics. 34 (2), 64–6.

    Google Scholar 

  39. Glenn, L.M. (2003) Biotechnology at the margins of personhood: An evolving legal paradigm, Journal of Evolution and Technology, 13, 110.

    Google Scholar 

  40. Ellis-Behnke, R.G., Liang, Y.X., You, S.W., Tay, D.K., Zhang, S., So, K.F., Schneider, G.E. (2006) Nano neuro knitting: peptide nanofiber scaffold for brain repair and axon regeneration with functional return of vision. Proc Natl Acad Sci USA, 103(13), 5054–9.

    Google Scholar 

  41. Sclabassi, R.J. (2009) Brain Implantable Computer Platforms, Presentation at Unither Technology Conference, Magog, Quebec. Available at http://www.unithertechnologyconference.com/downloads09/SessionsDayOne/SCLABASSI_web.pdf, last accessed November 6, 2009

  42. Kurzweil, R. (2005) The Singularity is Near: When Humans Transcend Biology, Viking Press.

    Google Scholar 

  43. Glenn, L.M. (2003) Biotechnology at the margins of personhood: An evolving legal paradigm, Journal of Evolution and Technology, 13, 110.

    Google Scholar 

  44. Glenn, L.M., Boyce, J.S. (2008) Nano­technology: Considering the Complex Ethical, Legal, and Societal Issues with Parameters of Human Performance, Nanoethics, 2, 265–275.

    Article  Google Scholar 

  45. McGee, E. (2009) Nanomedicine: Ethical concerns beyond diagnostics, drugs, and techniques. American Journal of Bioethics, 9(10), 14–15.

    Article  Google Scholar 

  46. McKibben, B.  (2003) Enough: Staying human in an engineered age, Times Books, New York.

    Google Scholar 

  47. McGee, E., (2007) Should there be a law: Brain chips: Ethical and policy issues. Thomas M. Cooley Law Review, 24(1), 81–97.

    Google Scholar 

  48. Jotterand, F. (2008) Beyond Therapy and Enhancement: The Alteration of Human Nature, NanoEthics, 2, 15–23

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Alden March Bioethics Center, Albany Medical Center, Albany, NY, USA

    Linda MacDonald Glenn

  2. Computer Science and Business, Montgomery College, Takoma Park, MD, USA

    Jeanann S. Boyce

Authors
  1. Linda MacDonald Glenn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeanann S. Boyce
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Linda MacDonald Glenn .

Editor information

Editors and Affiliations

  1. (IBEC), Inst. for Bioengineering of Catalonia, C/Baldiri Reixac 10-12, Barcelona, 08028, Spain

    Melba Navarro

  2. (IBEC), Inst. for Bioengineering of Catalonia, C/Baldiri Reixac 10-12, Barcelona, 08028, Spain

    Josep A. Planell

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Glenn, L.M., Boyce, J.S. (2012). Regenerative Nanomedicine: Ethical, Legal, and Social Issues. In: Navarro, M., Planell, J. (eds) Nanotechnology in Regenerative Medicine. Methods in Molecular Biology, vol 811. Humana Press. https://doi.org/10.1007/978-1-61779-388-2_19

Download citation

  • DOI: https://doi.org/10.1007/978-1-61779-388-2_19

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-61779-387-5

  • Online ISBN: 978-1-61779-388-2

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation